ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation

J. P. Knorr, C. Kallis, D. A. Portley, A. Jeyarajasingam, P. W. Lai, G. Bradauskaite, K. Khanmoradi

Transplant Nephrology, Einstein Medical Center, Philadelphia, PA

Meeting: 2020 American Transplant Congress

Abstract number: B-004

Keywords: Antibodies, HLA antibodies, Induction therapy, Kidney transplantation

Session Information

Session Name: Poster Session B: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and graft loss. While the optimal induction immunosuppressive therapy to prevent allograft rejection remains a topic of debate, only a scarce number of studies have investigated the difference in emergence of dnDSA following immunosuppression induction with alemtuzumab and thymoglobulin (ATG). We sought to compare the incidence of dnDSA between these two agents.

*Methods: We retrospectively analyzed 74 KTx recipients who were engrafted between 6/2017 and 7/2018 at our institution. Of these, 48 received ATG and 26 patients received alemtuzumab. Per protocol, patients underwent DSA screening at 1, 3, 6 and 12 months post-transplant. Mean fluorescence intensity (MFI) > 1000 was defined as positive. The evolution of preformed DSA, incidence of biopsy-proven acute rejection (BPAR) and survival at 1 year were also compared.

*Results: Patients were of comparable age, KDPI score and EPTS score in both groups. The population was largely of black race (ATG: 63% vs Alemtuzumab: 69%) with a median of 5 mismatched HLA antigens. There were statistically significantly more males and patients with cPRA >20% (58% vs 27%), and numerically more patients that were previously transplanted (15% vs 4%) or had a preformed DSA (23% vs 15%) in the ATG group. dnDSA are shown in Table 1. The incidence of dnDSA in the ATG group was 20.8% vs 11.5% in the alemtuzumab group (p=0.523). All four patients with preformed DSA in the alemtuzumab group cleared after KTx. Of the 11 with preformed DSA in the ATG group, two persisted with attenuated MFI following pre-transplant treatment with IVIG, one had increased MFI, and 8 disappeared post-transplant. There was one case of mixed BPAR in each group. There were two deaths in alemtuzumab group and one death in the ATG group, but no additional death-censored graft loss.

*Conclusions: Our study found higher occurrence of dnDSA in the ATG group, however this was not statistically significant. Since our sample size was small, and patients in the ATG group were of higher immunologic risk, larger, prospective randomized-control trials are needed.

1-year dnDSA
ATG (n=48) Alemtuzumab (n=26)

dnDSA MFI>1000, n (%)

10 (20.8)

3 (11.5)

0.523

dnDSA Class I, n (%)

6 (12.5)

3 (11.5)

dnDSA Class II, n (%) 6 (12.5) 1 (3.8)

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Knorr JP, Kallis C, Portley DA, Jeyarajasingam A, Lai PW, Bradauskaite G, Khanmoradi K. Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-1-year-incidence-of-de-novo-donor-specific-antibodies-between-thymoglobulin-and-alemtuzumab-induction-in-kidney-transplantation/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences